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ABSTRACT: The influenza virus is responsible for millions of
cases of severe illness annually. Yearly variance in the
effectiveness of vaccination, coupled with emerging drug
resistance, necessitates the development of new drugs to treat
influenza infections. One attractive target is the RNA-
dependent RNA polymerase PA subunit. Herein we report
the development of inhibitors of influenza PA endonuclease
derived from lead compounds identified from a metal-binding
pharmacophore (MBP) library screen. Pyromeconic acid and
derivatives thereof were found to be potent inhibitors of
endonuclease. Guided by modeling and previously reported
structural data, several sublibraries of molecules were elaborated from the MBP hits. Structure−activity relationships were
established, and more potent molecules were designed and synthesized using fragment growth and fragment merging strategies.
This approach ultimately resulted in the development of a lead compound with an IC50 value of 14 nM, which displayed an EC50
value of 2.1 μM against H1N1 influenza virus in MDCK cells.
■ INTRODUCTION
The influenza virus is responsible for annual seasonal epidemics,
resulting in 3−5 million yearly cases of severe illness and an
estimated 250 000−500 000 deaths worldwide.1 The past
century alone has seen the advent of four influenza pandemics,
each resulting in millions of deaths.2 While vaccinations are a
reasonable prophylactic for healthy adults, they must be re-
administered annually and are markedly less effective for
individuals with compromised immunity or similar high-risk
medical conditions. In addition, the efficacy of these vaccines is
heavily dependent on correctly predicting the predominant
infectious strains for any given year, and incorrect predictions can
render vaccination less than 25% effective.3 Existing drugs, such
as zanamivir (GlaxoSmithKline) and oseltamivir (Roche), which
target viral neuraminidase, can be useful in treating influenza
infections but must be administered within 1−2 days of infection
to be effective. These therapeutics also suffer from undesirable
side effects, including unusual neurologic or psychiatric events
such as delirium, hallucinations, confusion, and abnormal
behavior, primarily in children.4−6 M2 ion channel blockers
such as rimantadine (Sun Pharma) and amantadine (Endo) were
previously effective at inhibiting viral replication; however, 100%
of seasonal H3N2 and 2009 pandemic H1N1 influenza strains
now show resistance to these drugs.7,8 Considering this, there is
an urgent need for the development of new drugs to prevent and
treat influenza infection.
The influenza virus is a lipid-enveloped, negative-sense, single-
strand RNA virus. The viral genome is divided into 8 distinct
genomic segments, each encoding one or two of the 11 total viral
proteins.9 This segmented genome allows for the exchange of
segments between different viruses in infected host cells and,
coupled with the low fidelity of the viral RNA polymerase,
explains the high rates of drug resistance and antigenic shift seen
in influenza viruses.4,10 Each RNA segment is packaged in
complex with a single heterotrimeric RNA dependent RNA
polymerase.11 The polymerase complex comprises three distinct
subunits (PA, PB1, PB2) and is responsible for both transcription
and replication of the viral genome. However, the complex is
unable to synthesize the 5′-mRNA cap necessary for translation
by eukaryotic host-cell translation machinery. To overcome this
limitation, the polymerase hijacks a mature 5′-cap from host cell
pre-mRNA. This “cap-snatching”mechanism is accomplished by
the polymerase B2 subunit tightly binding the modified 5′-
guanine nucleotide with subsequent cleavage 10−13 nucleotides
downstream by the N-terminal endonuclease portion of the PA
subunit.12,13 The sequestered, capped RNA segment is then used
as a primer for viral mRNA synthesis, and the resulting hybrid
RNA is translated by the host cell.14
The viral polymerase complex is an attractive target for new
antiviral therapies. It is highly conserved across all influenza
strains and subtypes, and inhibitors should therefore have broad
efficacy against multiple serotypes. Of particular interest, the cap-
snatching mechanism is essential to the virus lifecycle, is
conserved in all members of the influenza virus family, and has
no human analogue.4 Cap-snatching, and subsequent viral
replication, has been shown to be inhibited by inactivating one
of two different domains of the viral polymerase complex: either
inhibiting the 5′-mRNA cap binding site on the PB2 subunit15−17
or inhibiting the N-terminal endonuclease portion of the PA
subunit.4,18,19
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The N-terminal domain of the PA subunit contains the
endonuclease active site. Crystallographic and biochemical
studies have shown the endonuclease to contain a dinuclear
metal active site, employing two Mn2+ or Mg2+ cations (Figure
1).13 The structure of the endonuclease domain closely
resembles type II restriction endonucleases,13 and it has been
shown that coordinating the metal centers of the endonuclease
active site effectively inhibits endonuclease activity. There are
currently no FDA approved endonuclease inhibitors, but several
classes of inhibitors have been reported in recent literature.
These include diketo acids,20,21 hydroxamic acids,22 flutimide
derivitives,23 green tea catechins,24,25 dihydroxypyrimidinones,26
3,2-hydroxypyridinones,27 and others. Most of these were
identified by experimental or computational high-throughput
screening (HTS) of large libraries and produced only modest
inhibitors in spite of great synthetic effort. More recently, some
very potent in vitro inhibitors have been identified.21,28,29
In an effort to efficiently identify novel, potent inhibitors of
influenza PA endonuclease, we carried out a fragment-based drug
discovery (FBDD) campaign, using a designer metal-binding
pharmacophore (MBP) library. This library is an expansion of
our prior report30 and consists of ∼300 fragment molecules
designed to interact with metal ions found in metalloenzyme
active sites. From this screening, pyromeconic acid was identified
as a ligand-efficient scaffold for inhibitor development. Guided
by modeling and SAR identified in the initial library screen, a
modest sublibrary of molecules was elaborated from the MBP
hits. Our metalloenzyme-focused FBDD approach ultimately
leads to molecules with potent in vitro inhibitory activity (IC50 <
50 nM) against viral PA endonuclease. The most potent of these,
1-(4-(1H-tetrazol-5-yl)phenyl)-2-(((4-chlorophenyl)(methyl)-
amino)methyl)-5-hydroxypyridin-4(1H)-one (71), was found to
inhibit endonuclease activity with an IC50 of 14 nM in enzymatic
assays. Compound 71 further showed good antiviral activity
against H1N1 influenza A virus in Marvin−Darby canine kidney
(MDCK) cells with an EC50 value of 2.1 μM and a CC50 value of
280 μM. These findings demonstrate that a metal-centric FBDD
approach can result in a rapid and efficient identification of
leadlike molecules, especially when compared to FBDD using
unbiased libraries or high-throughput screening.
Figure 1. Structural model of the influenza RNA-dependent RNA polymerase PA subunit (PDB code 4M5Q). The endonuclease active site employs
two divalent metal cations to facilitate the hydrolytic cleavage of the phosphodiester backbone of nucleic acids. Key active site residues and binding
pockets are highlighted. Pocket 2 is obscured by residue Tyr24. Divalent metal cations are shown as orange spheres with the bridging hydroxide anion
shown as a red sphere.
Table 1. Select MBP Fragments That Displayed Potent Inhibition against Influenza PA Endonuclease31,a
apIC50 is defined as pIC50 = −log(IC50) and is included to allow a linear comparison between IC50 values. Ligand efficiency (LE) provides a measure
of binding energy per non-hydrogen atom in the fragment molecule.
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■ RESULTS
MBP Library Screening. Fragments in theMBP library were
initially screened for endonuclease inhibition against the PA
subunit of the influenza polymerase complex. The screen was
performed using a FRET-labeled DNA oligonucleotide substrate
based on previously reported protocols with some minor
modifications (Supporting Information).13,28 Compounds that
exhibited >80% inhibition at a concentration of 200 μMwere re-
evaluated at a concentration of 50 μM. Dose−response curves
were compiled and IC50 values determined for fragments
exhibiting >50% inhibition at 50 μM. This screen identified
pyromeconic acid (1) as a moderate inhibitor of endonuclease
activity (IC50 = 22.5 μM; LE = 0.79) and unveiled important
structure−activity trends associated with simple modifications to
the hydroxypyrone ring (Table 1). A proposed mode of metal
coordination for 1 is shown in Figure 2. This model is based on
superposition of the donor atoms in 1with crystallographic water
molecules present in X-ray structures of uninhibited influenza PA
endonuclease and superposition of the pyrone ring with other
similar cyclic metal-binding inhibitors that have been crystallo-
graphically validated against the endonuclease.28
It was found that the addition of a methyl group to the 6-
position of the pyromeconic acid ring (2, allomaltol) had little
effect on the potency of the fragment, while the addition of a
methyl group to the 2-position (3, maltol) effectively abolished
activity. This is consistent with other endonuclease inhibitors
that employ a similar MBP motif, which demonstrates that
addition of substituents α to the hydroxyl donor atom reduces
potency.26,27 Addition of hydrophilic substituents in the 6-
position (4, 5) was well tolerated. The addition of a carboxylic
acid moiety to the 5-position, as in compound 6, afforded an
increase in potency, as did a methylamide derivative. Other
derivatives of 2 (6-position substituent) gave rise to modest
improvements in potency (8, 9).
Conversion of the pyrone ring to an N-methylpyridinone
resulted in a marked increase in potency, as seen in 9 and 10.
Pyridinones, as compared to pyrones, have more aromatic
character and greater electron density on the donating oxygen
atoms.32 This change in the electronic structure of the ligand
typically results in greater ligand basicity, which can lead to better
interactions with hard Lewis acidic metal centers, such as the
Mg2+ or Mn2+ found in the endonuclease active site.32 On the
basis of this preliminary SAR, synthetically feasible elaborations
were designed using pyromeconic acid derivatives as an MBP
core. Substitutions at the 1-, 5-, and 6-positions were deemed
most accessible and were evaluated independently.
5-Position Derivatives.On the basis of the SAR outlined in
Table 1, initial efforts focused on exploring amide derivatives of
compound 6/7. Guided by modeling and prior crystallographic
evidence,18,28 it was proposed that aryl substituents at the 5-
position could favorably interact with residue Tyr24 or residue
Arg84 or make favorable hydrophobic interactions with pocket 2
(Figure 1). A sublibrary of 11 arylamides derived from 6 were
synthesized and evaluated for inhibitory activity (Table 2). While
the methylamide 7 was equipotent to the parent fragment 6, all
arylamide derivatives were found to be less active. This trend
persisted regardless of additional functionalization of the aryl ring
or the introduction of methylene spacers between the amide and
aryl ring. The only exception to this trend was compound 20, a
tryptamine amide, but this derivative was not viewed as an
attractive lead based on the substantial increase in molecular
weight for little gain in activity. The resulting SAR suggested that
5-position amide functionalization was not a productive route to
more active inhibitors.
6-Position Derivatives. Initial SAR (8, 9) indicated that
hydrophilic substituents at the 6-position were well tolerated. To
continue probing interactions with pocket 2 (Figure 2), a series
of 6-aminomethyl derivatives were synthesized. Starting with
commercially available kojic acid, derivatives of the 6-position
could be readily prepared with amine, amide, and sulfonamide
linkages. Amine, amide, and sulfonamide derivatives were
between 3- and 18-fold more active than kojic acid (8), with
compound 31 being the most potent of the set. Arylamine and
ether, as well as benzylamine derivatives, displayed similar
activity, with tertiary amine derivatives being slightly more
potent than secondary amine derivatives (compound 26 vs 27;
32 vs 34). Functionalization of the aryl ring substituent in some
cases provided added potency; however, the introduction of a
pyridine substituent drastically decreased activity. Ultimately, the
SAR at the 6-position was relatively flat among aryl derivatives
but did indicate some gains could be made, with compound 35
identified as the most potent derivative of this set with an IC50
value of 0.94 ± 0.08 μM.
Pyridinone Derivatives. Conversion of the pyrone ring to a
pyridinone ring not only increases ligand basicity (and hence
metal binding) but also affords a chemical handle for facile
exploration of the large pocket located above the metal center
active site of endonuclease (Figure 2). To probe this pocket, a
sublibrary of N-substituted pyridinones was synthesized and
screened against endonuclease (Table 3). It was found that both
N-aryl- and N-cycloalkylpyridinones (compounds 44 and 47)
were significantly more active than the parent fragment
compound 10. Simple extension of the aryl substituent
(compounds 46 and 50) did not improve activity. Interestingly,
compounds 45 and 48 showed a significant loss in activity,
consistent with the previously observed negative effect of
substituents at the 2-position (compound 3, Table 1).
Figure 2. Proposed binding of pyromeconic acid (1) to the PA subunit
active site. Ring positions 5 and 6 were deemed amenable to further
derivatization for targeting hydrophobic pocket 2 and key residues
Tyr24 and Arg84. Derivatization at the ring position 1 was proposed to
probe interactions with pocket 4.
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In addition to elongation of the substituent, a series of more
polar, saturated, heterocyclic derivatives of 47 were prepared. As
detailed in Table 3, all of these derivatives showed reduced
activity, with modifications to the cyclohexyl moiety not being
well tolerated. The simple phenyl ring in compound 44 was
deemed more suitable for further synthetic elaboration.
A series of derivatives were synthesized exploring substituents
at either the 3′ or 4′ positions of the N-inserted phenyl ring
(Table 4). In general, 3′ modifications yielded a flat SAR, with
only small changes in activity. The SAR around the 4′ derivatives
was more varied and revealed that the addition of an aryl ether
(compound 60) or carboxylic acid (compound 62) both afforded
increases in activity. While several other polar 4′ derivatives
resulted in a reduced potency (64, 65, 66), the addition of a
tetrazole group to the 4′ position (63) resulted in a substantial
increase in potency. This finding is consistent with previous
Table 2. Inhibition Values of Various 5- and 6-Position Derivatives
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reports that phenyltetrazoles make very favorable interactions
with pocket 4.26−28 Compound 63 was identified as the most
potent derivative of this series with an IC50 value of 36 ± 7 nM
against PA endonuclease.
Fragment Merging. In an effort to maximize potency from
derivatives of pyromeconic acid (1), a fragment-merging strategy
was pursued. Computational modeling suggested that derivatives
at the 5- and 6-position were likely interacting with pocket 2 in
the endonuclease active site and that N-substituted derivatives at
the 1-position were interacting with pocket 4. It was decided to
merge the most potent 5- or 6-position derivatives with the most
potent 1-position N-aryl derivative to interact with both pockets
simultaneously. Because amide derivatization of compound 6
showed effectively no improvement to potency, incorporation of
a 5-position carboxylic acid to N-substituted compounds 44, 60,
and 63 was pursued. Ethyl esters 67, 68, and 69 surprisingly
showed markedly decreased potency after the addition of the
carboxylate group at the 5-position. Base catalyzed hydrolysis of
Table 3. Inhibition Values of Various N-Functionalized Hydroxypyridinones
Table 4. Inhibition Values and SAR of 3′ and 4′ Derivatives of 5-Hydroxy-2-methyl-1-phenylpyridin-4(1H)-one
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these compounds to produce the free carboxylic acid resulted in
complete degradation of these molecules; however, 70 was
synthesized via an alternative route. Disappointingly, 70 showed
no improvement over the parent compound 44. Due to the poor
inhibition shown by 70, further efforts toward 5-position
carboxylic acids were abandoned.
Extensive SAR of the 6-position revealed that arylamine and
sulfonamide derivatives were the most potent elaborations at this
position, likely due to favorable hydrophobic interactions with
pocket 2 and possible π-stacking interactions with Tyr24. As
detailed in Table 5, the addition of a 4-chloro-N-methylaniline
substituent to the already potent 63 resulted in a one-half log
increase in potency from an IC50 value of 36 ± 7 nM to 14 ± 3
nM for compound 71. While fragment merging did result in an
overall more potent molecule, the fact that the observed potency
increase was not more additive suggests either a conformational
change in binding mode as compared to the original fragments or
a possible overlap in binding pockets between the two
substituents.
Docking. In lieu of a cocrystal structure of 71 with
endonuclease (efforts are currently underway), docking studies
were performed to gain insight about the probable binding mode
of 71. Previously reported X-ray crystal structures of inhibitors
with similar MBPs bound to the endonuclease active site were
used as a starting point for these docking experiments.28 Using
Molecular Operating Environment (MOE) software, con-
strained docking and minimization studies were performed
starting from a reported endonuclease crystal structure with a
bound hydroxypyridinone-based inhibitor (PDB code 4M4Q,
Figure 3). The bound inhibitor was removed from the structure
and replaced with compound 71, utilizing the position of the
metal-coordinating donor atoms of the cocrystallized inhibitor as
an initial guide for the binding mode of 71. Constrained
minimizations were then performed on this model in which the
metal-binding oxygen atoms of 71 were fixed in optimal
geometries based on several parameters, primarily previous
crystal structures of inhibitors with similar ligand donor atom
identity and geometry.26,27 These constrained simulations ensure
that a reasonable metal binding geometry is maintained, as MM-
docking simulations do not appropriately account for metal−
ligand interactions.33,34 Flexible receptor modeling (induced fit)
was employed in which active site residue side chains proximal to
the inhibitor molecule were allowed to move, while residue
backbones were more constrained. In the simulation the
coordinating phenolic oxygen atom on inhibitor 71 was
deprotonated, and the charge on each metal center was assigned
as 2+ (i.e., Mn2+). Two water molecules coordinated to one of
the Mn2+ centers in the template structure (PDB code 4M4Q,
Mn302) were retained in the simulation, and their positions were
fixed relative to the metal center.
Analysis showed that the MBP chelates one of the active-site
metal ions, with the carbonyl oxygen atom replacing the bridging
water molecule and with the hydroxyl oxygen atom binding one
Table 5. Inhibition Values of Fragment Merged Inhibitors
Figure 3. Docking analysis of 71 in influenza PA endonuclease (PDB code 4M4Q). (a) Docked structure of 71 bound to endonuclease. Hydrophobic
interactions were found between the 6-position phenylaminomethyl moiety and hydrophobic pocket 2, as well as halogen bonding with Arg82. The N-
phenyltetrazole moiety was found to hydrogen-bond simultaneously to Arg124 and Lys34. (b) Ligand interaction diagram detailing ligand/protein/
solvent interactions rendered in two dimensions. Interactions between the ligand and protein active site are displayed as colored dotted lines:
coordination bonds in purple, hydrogen bonds and π−π interactions in green, and halogen bonds in blue. Blue halos indicate ameasure of ligand solvent-
exposure, with larger halos indicating greater exposure.
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metal center and forming a hydrogen bond with Lys134. The
phenylaminomethyl moiety at the 6-position was found to be too
short to allow for π-stacking with Tyr24 but allowed for
hydrophobic interactions with pocket 2. The 4-chloro
substituent is also positioned to allow for halogen bonding
with the backbone carbonyl of Arg82. The N-phenyltetrazole
moiety at the 1-position fits well into pocket 4, with the aryl ring
making hydrophobic interactions with the hydrophobic wall of
the pocket and the tetrazole making favorable contacts with the
basic residues found at the end of the pocket (Figure 3). It was
found that the 4′ tetrazole was able to hydrogen-bond with two
nitrogen atoms from the guanidine moiety of Arg124 and
simultaneously hydrogen-bond with the terminal nitrogen of
Lys34. The larger size and greater number of available hydrogen
bond acceptors in the tetrazole ring, when compared to a
carboxylic acid group, may account for the observed difference in
activity between the compounds containing these isosteres (62
vs 63).
Cytotoxicity and Antiviral Activity. Cytotoxicity and
antiviral activity studies were performed in MDCK cells
(Supporting Information). MDCK cells were incubated for a
period of 48 h in the presence of varying concentrations of
compound 71 or the commercially available diketo acid
compound 89 (L-742,001; Supporting Information), as a
control. Compound 89 is one of the most potent inhibitors of
influenza PA endonuclease reported, in both cellular and protein
based assays.19,35 Cell viability was then determined using
CellTiter-Glo luminescent assay (Promega). Antiviral activity
was determined by exposing MDCK cells to a lethal challenge of
influenza virus, in the presence of varying concentrations of
inhibitor. Influenza A virus obtained from the American Type
Culture Collection (H1N1, ATCC VR-1737) was used to infect
healthy MDCK cells, and inhibitor molecules were coadminis-
tered in varying concentrations with the viral challenge. The cells
were then incubated for 48 h and analyzed for viability via
luminescence assay. Compound 71 was found to have an EC50
value of 2.1 μM and a CC50 value of 280 μM (Figure 4). Both of
these values were comparable to the positive control (89), with
71 being 4- to 5-fold more potent than the control in the viral
challenge assay.
■ DISCUSSION AND CONCLUSIONS
Of the reported binding pockets in the influenza PA
endonuclease active site, many inhibitors that have been
structurally characterized in the active site interact with pocket
4. This common interaction space is due to the open nature of
pocket 4 (Figure 1, Figure 3), coupled with its proximity to the
catalytic metal ions that many inhibitors also interact with.18,25,28
A number of reported inhibitors interact with pocket 3 for similar
reasons.26,36 Fewer reported inhibitors have been shown to
interact with pocket 1 or pocket 2, with the only examples being
dioxobutanoic acid derivatives.18 Examples of inhibitors with
good interactions with pockets 3 and 4 include compounds
containing a phenyltetrazole moiety for pocket 4 (Figure 5).26,28
Figure 4. Potency and cytotoxicity analysis of 71 and a reported diketo acid inhibitor 89 in MDCK cell lines. Cytotoxicity was determined by incubating
cells in the presence of inhibitors for 48 h, followed by evaluating cell viability. Potency was determined by coadministration of inhibitor and a lethal
challenge of virus particles, followed by a 48 h incubation and subsequent analysis of cell viability.
Figure 5. Chemical structure and inhibitory activity of several reported influenza endonuclease inhibitors that contain a phenyltetrazole moiety.
Reported IC50 values for each compound are provided. TheMBP portion of each molecule is highlighted in blue. Compounds were initially reported by
Parhi et al.27 and Sagong et al.26
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Arnold and LaVoie initially identified a 5-chloro-3,2-hydrox-
ypyridinone as a fragment hit against endonuclease using a
crystallography-based fragment screening of 775 compounds.27
Fragment elaboration resulted in the development of Parhi-6
(Figure 5), which contains the aforementioned phenyltetrazole
moiety and displays a reported IC50 value of 368 ± 41 nM. In an
effort to develop even more potent inhibitors of endonuclease,
additional efforts lead to additional MBP heterocycle analogues
in combination with a phenyltetrazole substituent (Figure 5,
Figure 6).
The MPB scaffolds and elaborated inhibitors shown in Figure
5 were the result of a “scaffold hopping” campaign, which is
common in inhibitor development.37 Successful scaffold hopping
requires the identification of more potent, yet functionalizable,
core molecules. As such, the FBDD approach reported here was
able to further advance this strategy, using new MBP fragments,
resulting in compound 63 that exhibits improved activity over all
of these other derivatives shown in Figure 5. Therefore, the
MBP-based FBDD approach facilitates the identification of
potent core molecules and can allow for more effective and rapid
scaffold hopping, which also serves to further validate the
pharmacophore model and SAR observed in these prior
studies.26,28 The MBP library used here helps complement the
previous screening efforts by exploring a broader chemical space
of metal-binding functionality, rapidly identifying novel MBPs,
and providing significant improvements in activity. Furthermore,
by examination of other fragment sublibraries, a “fragment
growth” strategy was applied here, as demonstrated by
compound 71, which led to even greater enhancements in
activity by exploiting less-targeted active site pockets (pocket 2).
By employment of a FBDD strategy and use of a metal-
loenzyme-targeted MBP library, pyromeconic acid (1) and
similar fragments were identified as active inhibitors against the
influenza PA endonuclease. Prior work in the field, along with
modeling, allowed for the generation of a SAR, leading to the
synthesis of several pyrone and pyridinone derivatives based on
the initial fragment hits. Ultimately, five small molecules with in
vitro IC50 values of <200 nM, and two with IC50 values of <50
nM, were obtained. The most active compound (71) was found
to inhibit endonuclease activity with an IC50 of 14 nM.
Compound 71 showed minimal cytotoxicity with a CC50 of
280 μM and could rescue cells from a lethal challenge of H1N1
influenza virus with a viral EC50 of 2.1 μM. As opposed to other
reported screeningmethods, which generally involvemuch larger
libraries and more costly methods (e.g., crystallography), the
FBDD approach described here readily produced ligand efficient
fragments that targeted the metal active site. This targeted library
screening method shows the potential to be a more time- and
cost-effective route than those employed by traditional FBDD
and HTS campaigns, yielding a similar number of active hits and
ultimately resulting in the development of effective lead
molecules.
■ EXPERIMENTAL SECTION
General Experimental Details. All reagents and solvents were
obtained from commercial sources and used without further
Figure 6. Structural comparison of several phenyltetrazole-containing influenza endonuclease inhibitors. Left: Crystal structure of Sagong-11 (PDB
code 4W9S). Middle: Crystal structure of a derivative of Parhi-6 (PDB code 4M4Q). Right: Docking analysis of 71 (PDB code 4M4Q). Crystal
structures of phenyltetrazole-containing inhibitors show the binding orientation of the phenyltetrazole moiety to be essentially conserved. Docking
analysis of 71 predicts a very similar binding mode for this moiety to that observed in crystallographically validated inhibitors.
Scheme 1a
aReagents and conditions: (a) triethyl orthoformate, H2SO4 (catalytic), rt, 24 h; (b) 4-nitrophenyl trifluoroacetate, pyridine, rt, 18 h; (c) ethyl or
tert-butyl acetoacetate, NaH, reflux in dry THF, 4−6 h; (d) TFA, CH2Cl2, rt, 2−4 h; (e) HATU, triethylamine, DMF, 60 °C, o/n; (f) 1:1 HCOOH/
H2O, 80 °C, 2−6 h.
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purification. All reactions, unless otherwise stated, were performed
under a nitrogen atmosphere. Reactions were monitored using either
aluminum or glass-backed silica TLC plates impregnated with a
fluorescent indicator, absorbing at 254 nm. Silica gel column
chromatography was performed on a CombiFlash Rf Teledyne ISCO
system using hexane, ethyl acetate, methylene chloride, or methanol as
eluent. Reverse phase column chromatography (C18 column) was
performed on the same instrument using 0.1% formic acid in methanol,
acetonitrile, or water as eluent. Separations were monitored by mass
spectrometry via a Teledyne ISCO RF+ PurIon ESI-MS or APCI-MS
detector with 1 Da resolution. The purity of all compounds used in
assays was determined to be ≥95% by 1H NMR spectroscopy and
confirmed by high-resolution mass spectrometry (HRMS) experiments
using an Agilent 6230 Accurate-Mass LC-TOFMS located in the
University of California, San Diego, Molecular Mass Spectrometry
Facility (MMSF). Standard resolution MS was performed at either the
aforementioned MMSF or Teledyne ISCO RF+ PurIon MS. Microwave
reactions were performed using a CEM Discover series S-class
microwave reactor in pressure-sealed vessels. Docking simulations
were performed using MOE, version 2014.0901. Flexible receptor
modeling (induced fit) was employed in these simulations, and metal-
binding atoms were fixed.
Synthesis of 5-hydroxy-2-methyl-4-oxo-4H-pyran-3-carboxamide
derivatives is outlined in Scheme 1. Bromopyruvic acid was transformed
to bromodiethoxypropanoic acid by treatment with triethyl orthofor-
mate in the presence of catalytic sulfuric acid. The acetal-protected
propanoic acid was then activated as the p-nitrophenyl ester 74. Pyrone
ring formation was achieved over two steps by the slow addition of 74 to
a solution of ethyl or tert-butyl acetoacetate that was previously
deprotonated by sodium hydride. After the initial nucleophilic attack of
the activated ester by the acetoacetate, ring closing was accomplished via
nucleophilic addition by heating the reaction mixture to reflux for 4−6 h.
The pyrone-acetal 75a was deesterified by stirring briefly with
trifluoroacetic acid (TFA) in CH2Cl2. The tert-butyl ester was removed
selectively by controlling the time of the reaction, as the ester is more
labile in the absence of water than the acetal. Key intermediate 76 was
used to prepare various amides using analogous conditions; specifically,
76was activated with HATU and triethylamine in DMF. Addition of the
amine was followed by heating and stirring for ∼18 h at 60 °C. After
isolation of the formed amide the acetal was deprotected in water and
acid to reveal the 3-keto intermediate, which rapidly tautomerizes to
form the desired 3-hydroxide species.
To acquire SAR at the 6-position, a library of amine derivatives was
prepared from commercially available kojic acid (Scheme 2). The
phenolic oxygen of 8 was selectively protected as a benzyl ether by
treatment with benzyl bromide in the presence of potassium carbonate
in DMF at 80 °C. Compound 78was prepared quantitatively by reacting
77 with thionyl chloride. Nucleophilic addition of various primary and
secondary amines followed by selective hydrolysis of the benzyl ether in
a mixture of TFA, concentrated HCl, and glacial acetic acid afforded
aminomethylpyrones in good yields. Amide and sulfonamide derivatives
were generated by the nucleophilic addition of sodium azide to 78,
followed by reduction of 79 with triphenylphosphine to afford 80 as a
key intermediate. Compound 80 was reacted with various acid chlorides
and sulfonyl chlorides to generate 28−31, after deprotection of the
phenol by boron trichloride.
Preparation of pyridinone derivatives of allomaltol (2) possessing N-
aryl and -alkyl substituents is described generally in Scheme 3. Kojic
chloride (81) was derived from 8 and reduced to 2 using metallic zinc
and strong acid. While dehydration of the hydroxypyrone ring to afford
hydroxypyridinone derivatives was shown to be possible, benzyl
protection of the hydroxyl group prior to dehydration greatly improved
yields and suppressed formation of side products. Key intermediate 82
was irradiated in a microwave reactor in the presence of excess amine
and acetic acid to produce a wide variety of pyridinone derivatives.
Microwave heating under increased pressure greatly accelerated reaction
rates; dehydration using conventional heating could be accomplished
but required refluxing reactants in ethanol for a period of days. Removal
of the benzyl ether after dehydration was shown to be accomplished
quickly and efficiently employing boron trichloride as a dealkylating
agent or less efficiently using a 5:5:1 mixture of concentrated
hydrochloric acid, glacial acetic acid, and TFA, as a milder alternative
to boron trihalides (Supporting Information).
Scheme 2a
aReagents and conditions: (a) benzyl bromide, K2CO3, DMF, 80 °C, 8−12 h; (b) thionyl chloride, CH2Cl2, rt, 8 h; (c) R1R2NH, triethylamine,
DMF, 75 °C, o/n; (d) 5:5:1 HOAc/HCl/TFA, rt to 40 °C, 24−48 h; (e) sodium azide, DMF, rt, o/n; (f) triphenylphosphine, THF, rt, 30−60 min;
(g) acid chloride or sulfonyl chloride, CH2Cl2, rt, o/n; (h) BCl3, CH2Cl2, 0 °C, 30 min, rt, 30 min.
Scheme 3a
aReagents and conditions: (a) thionyl chloride, CH2Cl2, rt, 4−6 h; (b) zinc dust, HCl, water, 70 °C, 4−6 h; (c) benzyl bromide, K2CO3, DMF, 80
°C, 8−12 h; (d) aryl- or alkylamine, HOAc, 3:1 EtOH/H2O, microwave 125 °C, 90−120 min; (e) BCl3, CH2Cl2, 0 °C, 30 min, rt, 30 min; (f) 5:5:1
HOAc/HCl/TFA, rt to 40 °C, 24−48 h.
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Fragment merging was accomplished as shown in Scheme 4. Merging
of N-arylpyridinones with 5-position carboxylates began with advanced
intermediate 76a. Hydrolysis of the acetal followed by tautomerization
yielded 83. After benzyl protection of the phenol, dehydration was
accomplished with microwave heating using dry ethanol as a solvent.
Hydrolysis of only the benzyl ether using strong acid afforded
compounds 67−69 in moderate yields; hydrolysis of both ester and
ether was not observed. Further base catalyzed hydrolysis of the ethyl
ester proved difficult and ultimately resulted in the decomposition of the
ring system. As an alternative route, compound 86was hydrolyzed to the
free carboxylic acid by stirring in 4% KOH and methanol for several
hours. This reaction proceeded almost quantitatively with no apparent
decomposition of the starting material. Compound 86 was found to be
stable to strongly acidic conditions and was hydrolyzed to 70 using a
mixture of strong acids with good yields. Synthesis of compound 71
began with chloride compound 78. Nucleophilic substitution with 4-
chloro-N-methylaniline afforded pyrone 87. Dehydration, as previously
described, yielded 88 in moderate to low yields. Hydrolysis in the
presence of strong acid afforded 71.
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